We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

59 hedge funds and large institutions have $170M invested in Foghorn Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital invested

Capital invested by funds: $135M → $170M (+$35M)

6% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.03% less ownership

Funds ownership: 64.32% → 62.29% (-2%)

3% less funds holding

Funds holding: 61 → 59 (-2)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
59
Holders Change
-2
Holders Change %
-3.28%
% of All Funds
0.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
18
Reduced
17
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RJA
Raymond James & Associates
Florida
+$2.77M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.1M
3
Morgan Stanley
Morgan Stanley
New York
+$595K
4
SCM
Sio Capital Management
New York
+$525K
5
PAM
Panagora Asset Management
Massachusetts
+$269K

Top Sellers

1
AG
Artal Group
Luxembourg
-$4.31M
2
DM
Deerfield Management
New York
-$3.89M
3
GW
GW & Wade
Massachusetts
-$539K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$381K
5
BlackRock
BlackRock
New York
-$371K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$81.7M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$18.1M -$381K -88,210 -3%
RJA
3
Raymond James & Associates
Florida
$13.3M +$2.77M +642,161 +45%
EC
4
Euclidean Capital
New York
$10.2M – – –
BlackRock
5
BlackRock
New York
$8.42M -$371K -85,890 -6%
Vanguard Group
6
Vanguard Group
Pennsylvania
$6.61M +$27.8K +6,434 +0.6%
AG
7
Artal Group
Luxembourg
$4.65M -$4.31M -1,000,000 -58%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$3.48M +$1.1M +255,145 +90%
AI
9
Alphabet Inc
California
$3.23M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.89M +$96.1K +22,268 +5%
State Street
11
State Street
Massachusetts
$2.73M -$48.5K -11,240 -3%
DCM
12
Driehaus Capital Management
Illinois
$2.22M – – –
BC
13
Birchview Capital
Vermont
$2.07M +$242K +56,087 +21%
RWM
14
Rockwood Wealth Management
Pennsylvania
$1.38M – – –
Morgan Stanley
15
Morgan Stanley
New York
$1.36M +$595K +137,979 +191%
Northern Trust
16
Northern Trust
Illinois
$1.29M -$8.79K -2,037 -1%
SCM
17
Sio Capital Management
New York
$785K +$525K +121,672 New
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$694K +$253K +58,704 +120%
PAM
19
Panagora Asset Management
Massachusetts
$626K +$269K +62,441 +181%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$369K -$58.4K -13,534 -19%
Charles Schwab
21
Charles Schwab
California
$358K – – –
N
22
Nuveen
North Carolina
$348K +$2.08K +483 +0.9%
BBA
23
Baker Bros. Advisors
New York
$290K – – –
GCP
24
GSA Capital Partners
United Kingdom
$266K +$178K +41,295 New
Barclays
25
Barclays
United Kingdom
$212K +$127K +29,341 +823%
1
2 3

FHTX Hedge Fund Activity: Q4 2023 in Review

59 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q4 2023, worth a combined $170M — up 26% from $135M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of FHTX and 6 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 18 added.

The largest buyer was Raymond James & Associates, adding an estimated $2.77M. The largest seller was Artal Group, cutting an estimated $4.31M.

  • 59 institutional investors held Foghorn Therapeutics (FHTX) as of Q4 2023, down from 61 in Q3 2023.
  • Funds reported $170M of Foghorn Therapeutics stock for Q4 2023, up 26% quarter-over-quarter.
  • 6 funds opened new Foghorn Therapeutics positions in Q4 2023 and 8 closed out, a net change of -2 holders.
  • The largest Foghorn Therapeutics buyer in Q4 2023 was Raymond James & Associates, an estimated $2.77M added.
  • The largest Foghorn Therapeutics seller in Q4 2023 was Artal Group, an estimated $4.31M sold.

Based on aggregated 13F filings for Q4 2023.